Nonetheless, the drugs were shown to inhibit two targets related to thrombosis -PDE10A and TRPM6. PDE10A, which was recently validated as a novel target to treat pulmonary arterial hypertension (PAH) due to its central role in progressive pulmonary vascular remodeling, was identified as a target of baricitinib. The preliminary in vitro results of this study showed moderate inhibition of baricitinib for PDE10A2.